- « Previous
- Clinical Pharmacology
- Next »
Lorabid
Clinical Pharmacology
Clinical Pharmacology
Lorabid
Study 2: In a second controlled clinical study of cystitis, performed in Europe, loracarbef was compared to an oral quinolone. In this study, using very strict evaluability criteria and microbiologic and clinical response criteria at the 5- to 9-day post therapy follow-up, the following bacterial eradication rates were obtained (see TABLE 11).
| TABLE 11 European Uncomplicated Cystitis Study: Loracarbef vs Quinolone | ||
| Efficacy | ||
| Pathogen | % of Cases With Pathogens (n=189) | Outcome |
|---|---|---|
| E. coli | 82.0% | Loracarbef eradication rate 7% less than quinolone (loracarbef eradication rate 81%) |
| Other major Enterobacteriaceae | 10.1% | Loracarbef eradication rate 32% less than quinolone (loracarbef eradication rate 50%) |
Brand Name: Lorabid
Generic Name: Loracarbef
Generic Name: Loracarbef
- « Previous
- Clinical Pharmacology
- Next »
Bookmark this page:
Herbal First Aid
Herbal medicine is ancient, but only in recent years have many people started to take notice of its all natural healing powers. See more WebMD Videos »
WebMD Daily
Get breaking medical news.
Lorabid
Health Resources
2008 Election & Health Care on WebMD. Get Informed.
Updated & New
RxList does not provide medical advice, diagnosis or treatment.